Exploring the Relationship between Anti-VEGF Therapy and Glaucoma: Implications for Management Strategies

Research output: Contribution to journal › Review › Research › peer-review

Standard

Exploring the Relationship between Anti-VEGF Therapy and Glaucoma : Implications for Management Strategies. / Daka, Qëndresë; Špegel, Nina; Atanasovska Velkovska, Makedonka; Steblovnik, Tjaša; Kolko, Miriam; Neziri, Burim; Cvenkel, Barbara.

In: Journal of Clinical Medicine, Vol. 12, No. 14, 4674, 2023.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Daka, Q, Špegel, N, Atanasovska Velkovska, M, Steblovnik, T, Kolko, M, Neziri, B & Cvenkel, B 2023, 'Exploring the Relationship between Anti-VEGF Therapy and Glaucoma: Implications for Management Strategies', Journal of Clinical Medicine, vol. 12, no. 14, 4674. https://doi.org/10.3390/jcm12144674

APA

Daka, Q., Špegel, N., Atanasovska Velkovska, M., Steblovnik, T., Kolko, M., Neziri, B., & Cvenkel, B. (2023). Exploring the Relationship between Anti-VEGF Therapy and Glaucoma: Implications for Management Strategies. Journal of Clinical Medicine, 12(14), [4674]. https://doi.org/10.3390/jcm12144674

Vancouver

Daka Q, Špegel N, Atanasovska Velkovska M, Steblovnik T, Kolko M, Neziri B et al. Exploring the Relationship between Anti-VEGF Therapy and Glaucoma: Implications for Management Strategies. Journal of Clinical Medicine. 2023;12(14). 4674. https://doi.org/10.3390/jcm12144674

Author

Daka, Qëndresë ; Špegel, Nina ; Atanasovska Velkovska, Makedonka ; Steblovnik, Tjaša ; Kolko, Miriam ; Neziri, Burim ; Cvenkel, Barbara. / Exploring the Relationship between Anti-VEGF Therapy and Glaucoma : Implications for Management Strategies. In: Journal of Clinical Medicine. 2023 ; Vol. 12, No. 14.

Bibtex

@article{6fa08e7d116344399b5c14a32dbddbfe,
title = "Exploring the Relationship between Anti-VEGF Therapy and Glaucoma: Implications for Management Strategies",
abstract = "A short-term increase in intraocular pressure (IOP) is a common side effect after intravitreal anti-VEGF therapy, but a sustained increase in IOP with the development of secondary glaucoma has also been reported in some studies after repeated intravitreal anti-VEGF injections. The aim of this review is to present and discuss the possible pathophysiological mechanisms and factors contributing to a sustained rise in IOP, as well as treatment strategies for patients at risk. Close monitoring and adjustable IOP-lowering treatment are recommended for high-risk patients, including those with glaucoma, angle-closure anomalies, ocular hypertension or family history of glaucoma; patients receiving a high number of injections or at shorter intervals; and patients with capsulotomy. Strategies are needed to identify patients at risk in a timely manner and to prevent sustained elevation of IOP.",
keywords = "anti-VEGF, elevated intraocular pressure, glaucoma",
author = "Q{\"e}ndres{\"e} Daka and Nina {\v S}pegel and {Atanasovska Velkovska}, Makedonka and Tja{\v s}a Steblovnik and Miriam Kolko and Burim Neziri and Barbara Cvenkel",
note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",
year = "2023",
doi = "10.3390/jcm12144674",
language = "English",
volume = "12",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "M D P I AG",
number = "14",

}

RIS

TY - JOUR

T1 - Exploring the Relationship between Anti-VEGF Therapy and Glaucoma

T2 - Implications for Management Strategies

AU - Daka, Qëndresë

AU - Špegel, Nina

AU - Atanasovska Velkovska, Makedonka

AU - Steblovnik, Tjaša

AU - Kolko, Miriam

AU - Neziri, Burim

AU - Cvenkel, Barbara

N1 - Publisher Copyright: © 2023 by the authors.

PY - 2023

Y1 - 2023

N2 - A short-term increase in intraocular pressure (IOP) is a common side effect after intravitreal anti-VEGF therapy, but a sustained increase in IOP with the development of secondary glaucoma has also been reported in some studies after repeated intravitreal anti-VEGF injections. The aim of this review is to present and discuss the possible pathophysiological mechanisms and factors contributing to a sustained rise in IOP, as well as treatment strategies for patients at risk. Close monitoring and adjustable IOP-lowering treatment are recommended for high-risk patients, including those with glaucoma, angle-closure anomalies, ocular hypertension or family history of glaucoma; patients receiving a high number of injections or at shorter intervals; and patients with capsulotomy. Strategies are needed to identify patients at risk in a timely manner and to prevent sustained elevation of IOP.

AB - A short-term increase in intraocular pressure (IOP) is a common side effect after intravitreal anti-VEGF therapy, but a sustained increase in IOP with the development of secondary glaucoma has also been reported in some studies after repeated intravitreal anti-VEGF injections. The aim of this review is to present and discuss the possible pathophysiological mechanisms and factors contributing to a sustained rise in IOP, as well as treatment strategies for patients at risk. Close monitoring and adjustable IOP-lowering treatment are recommended for high-risk patients, including those with glaucoma, angle-closure anomalies, ocular hypertension or family history of glaucoma; patients receiving a high number of injections or at shorter intervals; and patients with capsulotomy. Strategies are needed to identify patients at risk in a timely manner and to prevent sustained elevation of IOP.

KW - anti-VEGF

KW - elevated intraocular pressure

KW - glaucoma

U2 - 10.3390/jcm12144674

DO - 10.3390/jcm12144674

M3 - Review

C2 - 37510790

AN - SCOPUS:85166354352

VL - 12

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 14

M1 - 4674

ER -

ID: 366508825